Healing Peptide Stack — BPC-157 + TB-500 + GHK-Cu Research and the 6-Week Protocol
The three-peptide healing stack — BPC-157 + TB-500 + GHK-Cu — sits at the convergence of three completely different research traditions: Sikiric's pentadecapeptide work, Goldstein's thymosin work, and Pickart's copper tripeptide work. None of the three drives healing through the same molecular mechanism as the other two, which is the entire reason the stack exists. This is the protocol breakdown for UAE peptide researchers running tendon, joint, or post-injury research.
1. The three peptides — what each one actually does
| Peptide | Primary mechanism | Tissue target | Key reference |
|---|---|---|---|
| BPC-157 | Angiogenesis (VEGFR2 ↑); tendon outgrowth via paxillin; NO system modulation | Tendon, ligament, gut, brain, vascular | Sikiric 2011; Chang 2011 |
| TB-500 | Actin remodelling; cell migration; β-thymosin family | Vascular, dermal, cardiac | Goldstein 2012; Crockford 2010; Smart 2007 |
| GHK-Cu | VEGF + HGF upregulation; collagen synthesis; decorin (TGF-β modulation) | Dermis, hair follicle, wound bed | Pickart 2018; Pyo 2007; Maquart 1988 |
The lack of mechanistic overlap is the entire case for the stack. BPC-157 grows new blood vessels into the healing site; TB-500 enables the cells in that healing site to migrate to where they're needed; GHK-Cu builds the collagen and matrix the migrated cells deposit.
2. The healing-process pipeline
Tissue healing follows a recognised four-phase process: haemostasis → inflammation → proliferation → remodelling. The three peptides intervene at different phases:
- Inflammation phase (days 1-7): BPC-157's NO-system modulation and anti-inflammatory effects begin here. GHK-Cu's decorin effect modulates TGF-β.
- Proliferation phase (days 4-21): BPC-157's VEGFR2 angiogenesis effect peaks. TB-500's actin/migration effect drives cell movement. Fibroblasts begin collagen deposition.
- Remodelling phase (weeks 3-6+): GHK-Cu's collagen synthesis effect dominates. Type I/III collagen ratios mature. Tensile strength approaches pre-injury values.
A single-peptide approach addresses one phase well. The stack addresses all four — which is the published-research-anchored rationale.
3. The protocol — the 6-week structure
Week 1-2: Loading phase
- BPC-157: 500 μg/day SC, morning, abdomen or thigh (alternating)
- TB-500: 2 mg SC twice weekly (Mon/Thu), abdomen alternating sides
- GHK-Cu: 2 mg/day SC, evening, abdomen OR 0.2% topical serum to skin/wound 2× daily
Week 3-6: Maintenance phase
- BPC-157: 250 μg/day SC (taper from loading)
- TB-500: 2 mg SC weekly (Mon)
- GHK-Cu: 1 mg/day SC OR 0.1% topical serum daily
Week 7-8: Optional taper
- BPC-157: 250 μg every other day, then stop
- TB-500: stop
- GHK-Cu: continue topical 0.1% if research endpoint is skin/wound
4. Injection logistics — three peptides, one body
Three separate peptides, three separate injections — never combined in one syringe (pH compatibility unknown). The practical scheduling:
| Time | Peptide | Site | Dose |
|---|---|---|---|
| Morning | BPC-157 | Lower abdomen, alternate sides daily | 250-500 μg |
| Mon + Thu (or Mon) | TB-500 | Upper outer thigh | 2 mg |
| Evening | GHK-Cu | Lower abdomen (different side from morning), OR topical to target area | 1-2 mg SC, or topical 0.1-0.2% |
Rotate injection sites within each peptide to avoid local irritation. The full sterile-technique walkthrough sits in our peptide reconstitution guide.
5. Vial math for the full stack
BPC-157 5 mg vial
- 5 mg + 2 mL bac water = 2.5 mg/mL
- 250 μg = 10 U-100 units; 500 μg = 20 units
- One vial covers ~10-20 days at 250-500 μg/day
TB-500 5 mg vial
- 5 mg + 2 mL bac water = 2.5 mg/mL
- 2 mg dose = 0.8 mL = 80 U-100 units
- One vial covers ~2.5 weeks loading (2× weekly) or 5 weeks maintenance (1× weekly)
GHK-Cu 50 or 100 mg vial
- 50 mg + 2 mL bac water = 25 mg/mL; 1 mg = 4 U, 2 mg = 8 U
- 100 mg + 2 mL bac water = 50 mg/mL; 1 mg = 2 U, 2 mg = 4 U
- Topical: 100 mg dissolved in 50 mL aqueous vehicle = 0.2% serum (50 mL covers ~6-8 weeks)
6. Total vial requirements for a 6-week stack
| Peptide | 6-week total | Vials needed |
|---|---|---|
| BPC-157 | ~12-15 mg (2 weeks at 500 + 4 weeks at 250 μg/day) | 3 × 5 mg vials |
| TB-500 | ~12-14 mg (2 weeks at 4 mg/wk + 4 weeks at 2 mg/wk) | 3 × 5 mg vials |
| GHK-Cu (SC) | ~42-56 mg (2 weeks at 2 + 4 weeks at 1 mg/day) | 1 × 100 mg vial |
| GHK-Cu (topical) | ~100 mg in 50-100 mL vehicle | 1 × 100 mg vial |
| Bacteriostatic water | ~9 mL across 3 vials reconstituted | 3 × 3 mL vials |
7. Tracking and endpoints
A 6-week protocol with no measurement is a waste of research-grade peptide. Minimum tracking framework:
- Baseline (Day 0): Pain VAS 0-10, range of motion measurement, photos if visible wound/skin
- Weekly check-ins: Same metrics, same time of day, same conditions
- Week 6 endpoint: Compare to baseline; calculate percentage change
- Post-cycle (week 8): Re-measure to assess persistence of effect
8. What the stack does NOT do
Researchers should hold realistic expectations:
- Doesn't replace mechanical load. Tendon and ligament tissue requires progressive loading to remodel correctly. Peptide stack accelerates healing capacity; load drives directional remodelling.
- Doesn't reverse structural damage. A torn meniscus is still torn; a ruptured tendon is still ruptured. Peptides support the healing of repaired tissue, not bypass repair.
- Doesn't work without sleep + nutrition. Protein intake, sleep, and inflammation control upstream of peptides matter — peptides amplify, they don't substitute.
9. The cost reality for UAE researchers
A full 6-week healing stack at UAE research-grade pricing:
- 3 × BPC-157 5 mg vials
- 3 × TB-500 5 mg vials
- 1 × GHK-Cu 100 mg vial
- 3 × Bac water 3 mL vials
- U-100 insulin syringes + alcohol pads + sharps container
This is the most-expensive layer of injectable stack in REVIVE LAB UAE's catalogue but still meaningfully below clinic-administered IV peptide protocols at AED 2,000-4,000 per session.
10. The summary
- BPC-157 + TB-500 + GHK-Cu address three non-overlapping healing mechanisms across the four-phase healing pipeline.
- Protocol: 6 weeks total with 2-week loading + 4-week maintenance + optional 2-week taper.
- Inject separately, rotate sites, never combine in one syringe.
- Total vial requirement: 3 BPC + 3 TB + 1 GHK + bac water for a single research protocol.
- No published randomised trial of the combined stack; mechanism-based synthesis.
- All three HPLC-verified at REVIVE LAB UAE with lot-level COA.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2011;17(16):1612-1632. PubMed
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011;110(3):774-780. PubMed
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci. 2018;19(7):1987. PubMed
- Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PubMed
- Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PubMed